Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Our Leadership

Meet Our Leadership Team

Janssen aims to change the way diseases are treated, and aggressively pursues new pathways, investigating new technologies and treatment modalities in Oncology, Immunology, NeuroscienceInfectious Diseases & Vaccines, Cardiovascular & Metabolism and Pulmonary Hypertension. Driven by our commitment to patients, we bring innovative products, services, and solutions to people throughout the world. We recognize the impact of serious conditions on people’s lives, and we aim to empower people through disease awareness, education and access to quality care.

As part of the Johnson & Johnson Family of Companies, the world’s most comprehensive and broadly based manufacturer of healthcare products, our promise is to deliver bold breakthroughs and meaningful medical innovation, and to never stop working toward a future where disease is a thing of the past.

Here is the leadership team that guides Janssen.



Joaquin Duato is a globally-experienced, values-driven health care business leader and currently Vice Chairman of the Executive Committee of Johnson & Johnson, the world’s premier health care company. Joaquin is responsible for the Company’s Pharmaceuticals and Consumer sectors, as well as Supply Chain, Information Technology, Global Services, and the Health and Wellness groups. He is a respected industry leader and is the immediate past Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Joaquin played an instrumental role in leading the turnaround of the Johnson & Johnson Pharmaceuticals sector. As a member of the Company for more than 30 years, Joaquin was named Company Group Chairman of the Americas in 2009. He then continued leading the global transformation upon his appointment to his most recent role as Executive Vice President and Worldwide Chairman, Pharmaceuticals in 2011. During that time, the sector grew into what is today the fourth-largest innovative pharmaceutical company globally. The results are clear: with 17 new products launched since 2011 and up to 10 potential billion-dollar medicines expected to be launched and/or filed before 2021, the Johnson & Johnson Pharmaceuticals sector is poised to extend its track record of seven years of above-market growth.

As a dual citizen of Spain and the United States with extensive experience living and working on-the-ground on multiple continents, Joaquin brings a unique international perspective to his work. His global experience has given him an appreciation for the value of diversity of thought and opinions, which he brings to bear externally as a UNICEF Board Member and the Tsinghua University School of Pharmaceutical Sciences Advisory Board Member,  and internally as the Executive Sponsor of the African American Leadership Council. His commitment to nurturing a culture of diversity was recognized in 2017 by the Healthcare Businesswomen’s Association (HBA) when he was named 2017 Honorable Mentor.

Joaquin also has a passion for learning, with an undergraduate degree in economics and business, a Master of Business Administration (MBA) degree from ESADE Business School in Barcelona, Spain, and a Master of International Management degree from Thunderbird in Phoenix, Arizona. He is a champion of improving access to both health literacy and education more broadly and recently completed his term as Board Member of the international charity, Save the Children. In addition, he mentors MBA candidates at universities around the world and speaks regularly on leadership in pharmaceuticals at industry forums and academic institutions.

Joaquin Duato

Vice Chairman of the Executive Committee
Johnson & Johnson


Vice Chairman of the Executive Committee
Chief Scientific Officer
Johnson & Johnson

Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.

Paul spearheads the Johnson & Johnson research pipeline by leading teams across all our sectors to set the company-wide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.

Paul’s commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to fuel innovative science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.

Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the pharmaceutical research and development pipeline of Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world.

Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and as Chairman of Tibotec, and led the development of a number of breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition.

Paul studied medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.

Paul Stoffels, M.D.

Vice Chairman of the Executive Committee
Chief Scientific Officer
Johnson & Johnson


Executive Vice President
Worldwide Chairman, Pharmaceuticals
Johnson & Johnson

Jennifer Taubert is Executive Vice President, Worldwide Chairman, Pharmaceuticals at Johnson & Johnson, the world’s largest health care company. She is a member of the Corporation’s Executive Committee and leads the Pharmaceuticals Group Operating Committee. 

Jennifer has been a leader in shaping Janssen’s global strategy of transformational medical innovation, successfully bringing to market critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, heart disease and diabetes, infectious diseases including HIV, pulmonary hypertension and serious mental illness. Under her leadership Janssen has become the world’s third-largest innovative pharmaceutical business and remains a significant contributor to Johnson & Johnson’s growth. Jennifer is also recognized as a champion of diversity, equity and inclusion, which she sees as critical to insight, innovation and business success.

Prior to being named to her current role, as Company Group Chairman, The Americas, Jennifer led businesses that were a major catalyst of Johnson & Johnson’s growth, doubling in size and consistently outpacing the industry to become the number one pharmaceutical company in the U.S. and Canada. Jennifer joined Johnson & Johnson in 2005 to lead global commercial strategy for Internal Medicine in the Pharmaceuticals Group. Later, as President, Internal Medicine, she built a powerhouse new franchise in cardiovascular and metabolic disease. Before joining Johnson & Johnson, Jennifer spent 18 years in positions of increasing scope and responsibility at Merck and Allergan. Jennifer was named to Fortune magazine’s “Most Powerful Women” list the past six years, and received the National Association for Female Executives’ 2017 “Woman of Achievement” award.

Jennifer represents Johnson & Johnson on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading innovative biopharmaceutical research companies. She also serves on the National Academy of Medicine’s Leadership Consortium: Collaboration for a Value & Science-Driven Learning Health System, and on the Advisory Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California.

Jennifer received a bachelor’s degree in Pharmacology from the University of California, Santa Barbara, and a Master of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.

Jennifer Taubert

Executive Vice President
Worldwide Chairman
Johnson & Johnson

Paul Anthony

Human Resources Head
Global Pharmaceuticals and External Innovation

Paul Anthony is Human Resources (HR) Head of Global Pharmaceuticals & External Innovation at Johnson & Johnson. Paul serves as a member of Johnson & Johnson’s Human Resource Executive Leadership Team, the Pharmaceutical Group Operating Committee and the R&D Management Committee. Paul leads HR strategy and operational excellence for the Pharmaceutical sector and Johnson & Johnson Innovation, including the Innovation Centers, JLABS, JJDC, the cross-sector Lung Cancer Initiative and Global Public Health.

Prior to this role, Paul was Head of Global Total Rewards and Human Capital Strategy at Johnson & Johnson, where he had responsibility for executive compensation, which encompassed working with the Board of Directors, Pension and Benefits Committee and Management Compensation Committees. Paul also had responsibility for compensation, benefits, acquisition and divestures, workforce analytics, health and wellness, HR strategy and transformation, HR talent and employee relations. 

Paul joined Johnson and Johnson in 2013 as the lead business partner for the Supply Chain organization supporting more than 55,000 employees globally. He played an integral role in advancing the Supply Chain operating model and partnered with organization’s leadership to champion innovation, talent and culture agendas. Paul also held responsibilities for successfully leading and executing the organizational transformation of Johnson & Johnson’s HR function in North America.  

Paul brings 25 years of diversified experience. Prior to Johnson & Johnson, Paul worked at Bristol Myers Squibb (BMS), where he was Senior Vice President, Human Resources, Commercial & Supply Chain and Chief Talent Officer. Prior to joining BMS, Paul worked at PepsiCo, Inc., as an HR Business Partner supporting Commercial, Supply Chain and Corporate functions. He started his career in Total Rewards and has held roles in Talent Acquisition and Labor Relations. 

Paul holds a Bachelor of Science Degree in Applied Mathematics and Statistics from the State University of New York at Stony Brook, and an Master’s in Business Administration from Northwestern University, Kellogg School of Management. 

Paul Anthony

Human Resources Head
Global Pharmaceuticals
and External Innovation



Pete Batesko is Vice President, Group Finance for the Pharmaceuticals Group of Johnson & Johnson.  In this position, Pete reports directly to Johnson & Johnson’s Chief Financial Officer, Dominic Caruso and provides finance leadership to the Pharmaceuticals Group, supporting Joaquin Duato and Paul Stoffels, as a member of the Group Operating Committee. He assumed this position on August 1, 2016.

Prior to taking this position, Pete served as Vice President, Group Finance and played a critical leadership role in the restructuring and transformation of our Medical Device Group.  Prior to this role, in June 2012, Pete was appointed Vice President, Group Finance for the DePuy Synthes Companies of Johnson & Johnson, where he managed all financial aspects of the Orthopaedic business worldwide and was a member of the Group Operating Committee.

From 2006 to 2012, Pete served as the Worldwide Vice President and Chief Financial Officer for DePuy Orthopaedics, Inc. In that role, he assisted with the acquisition of Synthes and the creation of the world’s most comprehensive orthopaedic and neurological company. From 2003-2006, Pete was the Vice President of Finance and Chief Financial Officer for Ortho Biotech Products, L.P. During that tenure, he oversaw all financial areas including health care compliance, process excellence and was part of the team that returned PROCRIT® to growth.

Pete has 35 years of Johnson & Johnson experience, beginning his career in 1981 as an auditor at headquarters in New Brunswick, New Jersey. From 1995 to 2003, he worked for Ortho-McNeil Pharmaceutical, Inc. as a controller. In that role, Pete led financial oversight of various groups including Business Development, Sales and Marketing.  During this time Pete was also a member of the team responsible for the acquisition of Centocor.

He earned his Bachelor of Science degree in Accounting from Villanova University, Villanova, Pennsylvania, and is a licensed certified Public Accountant (CPA) and Certified Management Accountant (CMA).

Pete Batesko

Vice President
Group Finance



Vanessa Broadhurst is Company Group Chairman, Global Commercial Strategy Organization (GCSO) and is a member of the Pharmaceuticals Group Operating Committee.

Prior to being named to this role, Vanessa was President, Cardiovascular & Metabolism (CVM) and a member of the Janssen Americas Leadership Team, a role she has held since May 2017. She also provided strategic oversight of the full portfolio of Janssen medicines in Puerto Rico and Canada. 

Prior to her CVM role, Vanessa was General Manager for the Bone Health and Cardiovascular Business Unit at Amgen. Previously, she was responsible for the Inflammation and Cardiovascular Business Unit at Amgen.

Vanessa originally joined Janssen in 2005. As Worldwide Vice President, Anemia/Oncology Supportive Care, she developed the global strategy for the franchise and drove therapeutic area development and growth. She also served as President of Janssen Therapeutics and Vice President of the Cardiovascular and Institutional Franchise before becoming President, Internal Medicine.

Prior to joining Janssen, she was with Novartis in Switzerland, where she was Head of Global Gastrointestinal Marketing. Vanessa started her career at Abbott, where she assumed her first General Management role in 2001, leading the U.S. Anti-Infective and Gastroenterology Business Unit. While at Abbott, she spent more than nine years in Marketing, Sales and Operational roles of increasing responsibility.

Vanessa is widely respected for her strategic insight and market acumen, as well as her commitment to talent development and diversity & inclusion. During her time with Janssen, she has served as Janssen America’s Sponsor of the African-American Leadership Council (AALC), MBA (ECLDP) Development Program and Culture Initiative, as well as former Executive Sponsor of the Woman’s Leadership Initiative (WLI). In 2018, Vanessa was named Woman of Excellence and Healthcare Champion of the Year by the National Association for Female Executives (NAFE).

Vanessa earned an MBA degree from the University of Michigan, where she was a Consortium for Graduate Study in Management Fellow, and a BA degree from the University of Colorado.

Vanessa Broadhurst


Remo Colarusso

Vice President
Janssen Supply Chain

Remo Colarusso is Vice President, Janssen Supply Chain (JSC) at Johnson & Johnson. In this capacity, Remo is responsible for the global manufacturing and supply management of all J&J pharmaceutical brands. He is a member of the Pharmaceutical Global Operating Committee (GOC) and the Johnson & Johnson Supply Chain (JJSC) Leadership Team.

Remo has more than 30 years of biotech and pharmaceutical experience with Johnson & Johnson in the areas of manufacturing, pharmaceutical development, planning, strategy, engineering, project management and process improvement (Lean/Six Sigma). Over the course of his career at Johnson & Johnson, he has held a variety of diverse, strategic leadership roles in the Pharmaceuticals (Janssen) sector, including Vice President, Manufacturing and Technical Operations (MTO), Vice President of Pharmaceutical Development & Manufacturing Sciences (PDMS) in the Research & Development Operations organization, and Vice-President, Product Management, where he was responsible for planning, new product introduction and product lifecycle management. Prior to joining Johnson & Johnson, Remo held roles in engineering at JM Huber Corporation and in process development at the Colgate Palmolive Company. 

Over the course of his distinguished career, Remo has been recognized for his tireless commitment to driving supply chain innovation and continuous improvement to deliver maximum value for customers and patients. Personally, he is a strong advocate for diversity and inclusion and focuses a lot of his time mentoring the next generation of industry leaders.

Remo is an active member of numerous organizations designed to support the leadership development and advancement of our industry. He is an active member in the Global Pharmaceutical Manufacturing Leaders Forum Committee of the International Society of Pharmaceutical Engineers (ISPE) and a member of the Pharmaceutical Manufacturers Forum with other supply chain senior leaders from across the pharmaceutical industry.  He also participates in the National Association of Manufacturers to further manufacturing excellence in the United States.

Remo holds a Bachelor of Science in Chemical Engineering and an MBA in Operations Research, both from Rutgers University.

Remo Colarusso

Vice President
Janssen Supply Chain



Linda Fedow is Global Lead, Pharmaceuticals Communication & Public Affairs. She assumed this position in May 2012.

In this role, Linda is responsible for building the equity and reputation of Janssen as a leading global pharmaceuticals business and has accountability for the internal and external communication teams supporting Janssen around the world. She is a member of the Pharmaceuticals Group Operating Committee (GOC) and the Corporate Communication Leadership Team.

Prior to assuming her current role, Linda served as Vice President, Communication & Public Affairs, the Americas, in the Pharmaceuticals Group. As a member of the North America Leadership Team, she was responsible for developing communication and public affairs strategies to support the commercial objectives of the Janssen businesses in the United States, Latin America and Canada.

Previously, Linda was Vice President, Group Communications for the Comprehensive Care Group and served on its Group Operating Committee. In that role, she had dual responsibility, also serving as the global communication leader for the Ortho-Clinical Diagnostics franchise.

Linda joined the Johnson & Johnson Family of Companies in 1997 from a major international public relations agency, where she was responsible for marketing communications and wellness management strategies for consumer, healthcare, and food and beverage products. During her career at Johnson & Johnson, she has had regional and global accountabilities for the communication function within a number of operating companies and franchises, including women's health, central nervous system, analgesia, biopharmaceuticals and internal medicine.

Linda holds Bachelor of Science and Master of Arts degrees in Biology from the City University of New York.

Linda Fedow

Global Lead
Pharmaceuticals Communication & Public Affairs


General Counsel

Liz Forminard is General Counsel, Pharmaceuticals and is responsible for legal matters relating to the Pharmaceuticals Group globally. In addition, the Legal group providing support to Johnson & Johnson Global External Innovation also reports into Liz, and she will continue to play a leadership role in our external engagement with key corporate governance stakeholder organizations. 

Most recently Liz served as Worldwide Vice President, Corporate Governance and led the Office of the Corporate Secretary and the Enterprise Governance and Policy Group. She also served as General Counsel of the Global Supply Chain and Procurement organizations. As WW VP, Corporate Governance, Liz worked closely with our Chairman and CEO, the Executive Committee and our Board of Directors on corporate governance matters across the Enterprise. She also led the work to transform Johnson & Johnson’s external sustainability reporting in our Health for Humanity Report.

In her prior roles as a member of the Law Department Executive Committee, Liz was General Counsel, Consumer Group, with global responsibility for legal matters across Johnson & Johnson’s Consumer companies and oversaw legal support for the Global Supply Chain and Procurement organizations. Liz also previously served as General Counsel, Medical Devices & Diagnostics Group. 

Since joining Johnson & Johnson in 2006, Liz has served as Vice President Health Care Compliance, Medical Devices & Diagnostics; Worldwide Vice President Law at Ethicon; and Vice President Law for the Johnson & Johnson Consumer Healthcare Global Business Unit.

Before joining Johnson & Johnson, Liz developed extensive regulatory legal experience as an associate at the law firm Weil, Gotshal & Manges, and in the United States and Asia-Pacific legal operations of Pfizer Consumer Healthcare.

Liz holds a B.A. degree from Cornell University and a Juris Doctor (J.D.) degree from the University of Pennsylvania School of Law.

Elizabeth Forminard

General Counsel



Chris Hourigan is Company Group Chairman of Janssen Asia Pacific, where he oversees pharmaceutical operations across eight markets in the world’s most diverse and populous region. He is also a member of the Pharmaceuticals Group Operating Committee.

For the five years prior to this appointment, Chris was President of Janssen Japan, the second largest market for Janssen globally. Under his leadership, he improved the company’s market competitiveness, widened access to innovative medicines, and attracted and developed strong talent.

Prior to this role, he held leadership positions in Australia, Vietnam and New Zealand and made a meaningful difference in the lives of patients by working collaboratively with a range of health and pharmaceutical stakeholders to establish access to and foster the quality use of innovative medicines. He also worked in the United States as Global Marketing Lead for the Janssen Psychiatry business unit.

Chris is a highly respected member of the pharmaceutical industry, having chaired Pharmaceutical Research and Manufacturers of America (PhRMA) Japan and served as a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, Medicines Australia and Medicines New Zealand to highlight the value of pharmaceutical innovation and advocate for access to medicines.

Chris holds a Master of Business Administration and a Bachelor of Applied Science from the University of Technology, Sydney, Australia.

Chris Hourigan

Company Group Chairman
Asia Pacific



Robin L. Kumoluyi is Vice President and Chief Quality Officer, Johnson & Johnson, Pharmaceuticals. Robin also is a member of the Johnson & Johnson Quality and Compliance Leadership Team (QCLT), as well as the Pharmaceuticals Group Operating Committee (GOC).

In her current role, Robin leads the Pharmaceuticals QCLT in setting the quality and regulatory compliance strategy, leads the implementation of quality processes and systems, and develops talent to strengthen Johnson & Johnson’s quality and compliance profile and leadership position in the pharmaceutical industry.

Most recently as Vice President, Global Quality Systems (GQS), Robin implemented a new operating model that refined and focused the work of the enterprise team to better align with the businesses and gain efficiencies. She also defined and executed the strategic direction, development and oversight of the Q&C Strategy to prepare for our future innovative products and solutions while preserving our core foundation.

With more than 30 years of experience in quality and compliance and R&D, Robin brings a strong quality and technical skill set across a broad range of product categories to her new role. Prior to joining Johnson & Johnson in 2016, Robin served as the Vice President & Global Head, Third Party Operations Novartis Business Services, where she had global responsibility for the governance of the quality management of external supply partners across all Novartis divisions. Prior to Novartis, Robin held global roles with increasing levels of responsibilities within Q&C at Myogen, Schering-Plough and Warner Lambert/Pfizer. In addition, Robin gained Consumer experience from her tenure at The Coca Cola Corporation where she served as Director Global Quality Analytical Services.

Robin has been heavily involved in shaping the future within the pharmaceutical industry, participating in many industry working groups and forums, including the Consortium for Advanced Manufacturing of Pharmaceuticals (CAMP), PDA, DIA, ISPE, Rx360 and most recently, the Global Pharmaceutical Manufacturing Leadership Forum (GPMLF) where she is representing J&J in a working group focusing on the workforce of the future.

Robin holds a master’s degree in Quality Assurance/Regulatory Affairs from the School of Pharmacy at Temple University and a bachelor’s degree in Biological Sciences from Rutgers University.

Robin L. Kumoluyi

Vice President & Chief Quality Officer
Johnson & Johnson



As Global Oncology Therapeutic Area Head for the Janssen Pharmaceutical Companies of Johnson & Johnson, Peter F. Lebowitz, M.D., Ph.D. is responsible for the discovery, development and life cycle advancement of the company’s robust oncology pipeline and portfolio. He leads a global team of scientists that bring together expertise in small molecules, advanced biologics, cell therapies, vaccine platforms, translational research, diagnostics, and immuno-oncology. Under Peter’s leadership, Janssen Oncology has achieved many noteworthy milestones, including major product approvals for several first-in-class therapies; multiple U.S. Food and Drug Administration Breakthrough Therapy Designations; and tremendous, rapid growth within the group’s early development portfolio.

With a strategy focused on driving towards transformational therapies, Peter also successfully established an external innovation strategy to advance science and novel therapeutics in core disease areas, including hematologic malignancies, prostate cancer, immuno-oncology, and lung cancer. The combination of these efforts has led to more than 80 strategic oncology partnerships across the life sciences ecosystem and continues to distinguish Janssen as an industry leader and global oncology innovator.

Prior to his appointment as Global Oncology Therapeutic Area Head, Peter served as the Hematologic Malignancies Disease Area Leader within Janssen Research & Development. In this role, he had responsibility for creating and executing the scientific strategy to advance internal and externally sourced discovery and development programs. Together with his team, Peter is recognized for building an industry-leading hematologic malignancies portfolio that has been foundational for scientific innovation and has progressed important therapeutics that have transformed patient care.

Before joining Janssen R&D, Peter held Vice President positions in Discovery and Early/Late-stage Clinical Development for another pharmaceutical company where he successfully filed 10 Investigational New Drug Applications and played a significant role in the global registration of three oncology medicines. During his tenure, he also directly led major programs from preclinical discovery through pivotal Phase 3 registration trials.

Prior to transitioning to the pharmaceutical industry, Peter served as Assistant Professor of Medicine, Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center.  There he established an independently funded translational and clinical research program and led numerous clinical research programs as a principal investigator. He also had the privilege of caring for many oncology patients during this time.  Peter graduated magna cum laude from Harvard University, holds a master’s degree in Health Care Policy from Oxford University, and earned his medical degree and doctorate from the University of Pennsylvania School of Medicine. He completed clinical training in Internal Medicine at Duke University Medicinal Center and his Hematology/Oncology fellowship at the National Cancer Institute, National Institutes of Health. He is board-certified in Internal Medicine and Medical Oncology.

Peter Lebowitz, M.D., Ph.D.

Global Therapeutic Area Head



Joyce Lee is the Chief Information Officer (CIO), Pharmaceuticals. Joyce also serves on the Pharmaceuticals Group Operating Committee (GOC).

Previously, Joyce served as Vice President and CIO of VF Corporation, Asia Pacific. During her tenure, Joyce was a key member of two Senior VF Asia Executive Leadership teams, where she oversaw Information Technology (IT) strategy for VF Commercial brands and Global Product Supply. Joyce played a strategic role in leading and developing retail excellence and digital eCommerce technology innovation through collaborations with China digital titans including Alibaba and Tencent. She also successfully led the regional technology separation of a complex business spin-off initiative.

Prior to her role with VF corporation, Joyce was the Vice President and CIO of the Americas region for Janssen Pharmaceuticals. In this role, Joyce was a strategic member of the Janssen Americas Leadership Team and focused on IT strategy and developing and leading teams. Joyce worked in close collaboration with key pharmaceutical business stakeholders to drive transformation and value creation using innovative technology capabilities such as next generation digital patient access and support solutions. She modernized Medical Affairs and Medical Information capabilities, and enhanced customer engagement, data insight-driven and predictive solutions using advanced analytics to improve patient adherence and outcomes.

In addition to being a strategic technology leader, Joyce has proven business management capabilities and direct Profit & Loss experience. In an earlier role as Managing Director, Johnson & Johnson Consumer, Malaysia and Singapore, she led a diverse range of Johnson & Johnson Consumer personal care, healthcare and over-the-counter brands. Some of her key achievements included three years of consecutive double-digit top- and bottom-line growth and successful implementation of a new go-to-market sales business model.

Joyce Lee

Chief Information Officer



David M. Lee, M.D., Ph.D., is Global Immunology Therapeutic Area Head for the Janssen Pharmaceutical Companies of Johnson & Johnson where he leads a team focused on end-to-end pipeline and a portfolio of treatments for immune-mediated disease. Under his leadership, Immunology researchers are working to build on the success of our current portfolio, which includes STELARA® (ustekinumab) and TREMFYA® (guselkumab).

Prior to joining Johnson & Johnson in September 2018, David was based in Basel, Switzerland, where he served as Global Head, Immunology, Inflammation and Infectious Disease Discovery and Translation Area for Roche, and prior to that, as Global Head of Autoimmunity, Dermatology, and Transplant Translational Medicine at the Novartis Institutes for BioMedical Research. In each of these roles, he led on the strategic approaches that fed the companies’ pipelines, prioritized assets, and accelerated their development. His ability to develop external collaborations and lead and develop his teams, was central to his success in each organization.

Before transitioning to the pharmaceutical industry, David was a faculty member at Brigham and Women’s Hospital/Harvard Medical School. While there, his research laboratory focused on disease mechanisms in rheumatology and he was also a practicing rheumatologist. As a precursor to his career in industry, while at Harvard, he also participated in co-founding multiple start-ups. Ultimately, one – a biotech – was acquired by a major pharmaceutical company.

He is an active author and speaker, and has completed more than 80 peer-reviewed publications, book chapters, and more than 100 lectures/seminars.

David earned his undergraduate degree at Stanford University, where he discovered his fascination with the intricacies of the immune system. He subsequently earned his M.D. and Ph.D. in Microbiology/Immunology from the Duke University School of Medicine. His passion for developing new medicines is rooted in his experiences treating patients as a practicing rheumatologist.

Follow David on LinkedIn here.

David M. Lee, M.D., Ph.D.

Global Therapeutic Area Head



As Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, Mathai’s mission is to focus the energy of the best research and development teams in the world at the intersection of profound unmet medical need and actionable breakthroughs in science and technology to make medicines of unequivocal benefit for humanity.  The team works across a wide range of therapeutic areas and biological pathways. Janssen’s approach to medicines is patient-focused, agnostic to both source of the idea and the treatment modality.  The team is invested deeply in data sciences in every aspect of R&D.  Janssen R&D has fueled the growth of Janssen to be the largest pharmaceutical company in the United States, and the fourth largest in the world.

Prior to joining Janssen in June 2017, Mathai was Senior Vice President at Merck Research Laboratories, responsible for research in the areas of Cardiovascular, Metabolic and Renal Diseases, Oncology/Immuno-Oncology and Immunology. Jointly with his team, he initiated numerous new programs and progressed eight into early clinical development. Prior to Merck, Mathai led R&D at Theravance, a company he co-founded in the San Francisco Bay Area in 1997 based on his work at Harvard University. His talented team of 200 scientists nominated 31 development candidates in 17 years, created five approved products and created a pipeline containing many additional late development-stage compounds. In 2014, he and the Theravance Leadership Team separated Theravance into two publicly traded companies: Innoviva (INVA) and Theravance Biopharma (TBPH).

Mathai has more than 150 peer-reviewed publications and patents and serves on various boards and advisory committees. He received his M.D. from Harvard Medical School/Massachusetts Institute of Technology (HST program) and his Ph.D. in Chemistry from Harvard University's Department of Chemistry, working with George Whitesides. He received his BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

Mathai Mammen, M.D., Ph.D.

Global Head
Research And Development



Since starting his career at Janssen in Belgium almost 30 years ago, Kris Sterkens has been part of many teams across EMEA, Asia Pacific, and the United States.

Moving on from his latest role as the Company Group Chairman of Janssen Asia Pacific, Kris was appointed Company Group Chairman of Europe, Middle East and Africa in June 2017. He was excited to return to his home country, Belgium, after spending over three years in Singapore since February 2014 for the Asia Pacific business.

Under Kris’ stewardship, Janssen Asia Pacific achieved notable milestones, including a return to growth in China and a successful business transformation in Japan. Kris also led teams in Korea, Australia, and New Zealand and successfully competed against new biosimilar entrant, in addition to achieving industry-leading growth in India. Throughout his career, Kris has demonstrated exceptional leadership and an ability to identify and develop talent. For instance, in Asia Pacific, he introduced Company Group Chairman’s Dialogue, a talent development programme which has engaged more than 100 emerging leaders.

Prior to that, Kris was leading the EMEA Strategy Organisation, alongside his role as Managing Director of the region’s Mid-Sized Markets. He was also the Managing Director for Janssen the Netherlands, the Benelux countries, and then Germany from 2007–2012.

Before his transition into General Management, Kris was Vice President, Finance and Chief Finance Officer (CFO) for Janssen EMEA.

Kris holds a Master’s degree in Applied Economics from the University of Antwerp, a Master's degree in Financial Management from the Flemish Institute of Management, and an MBA from the Solvay Business School in Brussels. Kris is fluent in Dutch, English, German, and French and has been a frequent speaker at business schools, medical and patient group events, and industry meetings.

Kris Sterkens

Company Group Chairman
Europe, Middle East, and Africa


Global Head
Discovery, Product Development & Supply
Janssen Research & Development

Richard Tillyer, Ph.D, is Global Head, Discovery, Product Development & Supply, Janssen Research and Development. In this role, he leads an integrated discovery, process development and clinical supply organization that comprises all modalities including small molecules, traditional and non-traditional single molecule biologics, and larger, more complex multicomponent biologics including RNA, viruses and cells.

Rich joined Janssen in 2018 from Merck & Co (MSD outside the United States), where he acquired extensive experience in all stages of drug discovery and product development across numerous therapeutic areas and modalities. During his 25-year tenure, he led large and varying aspects of Merck Research Labs, including Process Chemistry, Toxicology, Drug Metabolism and Pharmacokinetics, Formulation, Biologics and Vaccines Process Development, High Throughput Screening, Discovery Biology, Medicinal Chemistry, Computational Chemistry and various platform groups. Under his leadership, Rich’s teams contributed to the discovery and development of most major products introduced by Merck over the last two decades and significantly advanced the company’s current pipeline. He led or actively contributed to major strategic initiatives including large and small-scale mergers and R&D integrations (most notably, the integration of Schering-Plough announced in 2009).

Rich obtained his Ph.D. in Chemistry from the University of British Columbia, Canada, and a post-doctoral research fellowship in Chemistry from the University of Cambridge, UK. He has published more than 70 scientific articles and publications and he holds several patents.

Richard Tillyer, Ph.D.

Global Head
Discovery, Product Development and Supply
Janssen Research & Development



Patrick Verheyen is Global Head, Janssen Business Development. In this role, Patrick leads the business development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals for the Janssen Pharmaceutical Companies of Johnson & Johnson. Patrick assumed this role in April 2015.

Prior to this, Patrick helped design and launch Johnson & Johnson Innovation and was the Head of Johnson & Johnson Innovation, London. This Innovation strategy has delivered a robust early-stage portfolio and has helped earn Johnson & Johnson a reputation as a preferred partner with external innovators, entrepreneurs and academic institutions.

Patrick joined Johnson & Johnson in 1986 at Janssen Pharmaceuticals in Beerse, Belgium.  He has held several leadership roles within our Pharmaceuticals organization including Vice President, New Ventures, Pharmaceuticals, where he led an agile and diverse team who facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow.  Patrick also served as Vice President, M&A, where he facilitated strategic collaborations and acquisitions including Crucell, Elan and Cougar Biotechnology, and established spin-out companies, including Movetis.  Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large capital space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations, private equity groups and government institutions.

Before beginning his professional career, he studied bioengineering at the University of Leuven, Flanders, Belgium.

Patrick Verheyen

Global Head
Janssen Business Development


Company Group Chairman
North America Pharmaceuticals
Johnson & Johnson

Scott White is Company Group Chairman, North America, at the Janssen Pharmaceutical Companies of Johnson & Johnson. A member of the Pharmaceuticals Group Operating Committee, he is responsible for leading Janssen’s efforts to transform the health of people in the U.S. and Canada facing cancer, autoimmune disease, heart disease and diabetes, infectious diseases including HIV, pulmonary arterial hypertension, and serious mental illness.

In his 28-year career at Janssen, Scott has led some of our most significant businesses across multiple serious disease areas. He is a results-focused leader, widely respected for his strategic insight and commitment to developing high-performing, diverse teams.

As President, Janssen U.S. Immunology, Scott led Johnson & Johnson’s largest business, making a significant difference for people with debilitating autoimmune diseases through highly impactful medicines including REMICADE®, STELARA®, SIMPONI®, SIMPONI ARIA® and TREMFYA®, and innovative patient support and access programs. Prior to his Immunology role, Scott was President of Janssen U.S. Oncology. Under Scott’s leadership, Janssen launched two transformational cancer treatments, IMBRUVICA® for chronic lymphocytic leukemia and DARZALEX® for multiple myeloma, making Janssen Oncology one of the fastest growing oncology businesses in the U.S. Previously, Scott held the position of Vice President, Strategic Customer Group, serving all Janssen U.S. businesses, where he led contracting and account management. In this critical role, he served as the market access leader to ensure people who need our medicines have access to them.

Scott holds a Bachelor of Arts from Rutgers, The State University of New Jersey, where he double-majored in molecular biology and philosophy. He also received a Master of Business Administration from the University of Phoenix.

Scott White

Company Group Chairman
North America Pharmaceuticals
Johnson & Johnson